INDICATION AND IMPORTANT SAFETY INFORMATION
TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.  ...More

A CLOSER LOOK AT PULMOSPHERE™ PARTICLES

Click here to launch Progressive Video Player

TOBI® Podhaler®: PulmoSphere particles

Reproduced with permission from Geller DE et al.1 Particles are not actual size.

  • PulmoSphere particles: a different type of dry powder
  • Low-density particles are light and porous1
  • 85% of the total mass of dry powder is composed of tobramycin sulfate2
  • Particle size: median geometric diameter is 1.7 to 2.7 μm1
  • TOBI Podhaler delivers medication to the central and peripheral airways3,4

A centralized support and access program for TOBI® Podhaler® patients

Learn more

SET TREATMENT EXPECTATIONS

Inform your patients about what to expect while taking TOBI® Podhaler®

Learn more

ADMINISTRATION INFORMATION

Administration information and helpful tips for patients taking TOBI® Podhaler®

Learn more

Share

To share this website with other health care professionals, please choose your email service provider:

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in
1 second
(FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.